



May 14, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Ltd.,**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of the Establishment Inspection Report from the U.S. FDA after closure of the inspection for the Company's Vizag (Vishakhapatnam), India facility. The inspection for the said API facility was conducted by U.S. FDA between January 13, 2020 and January 17, 2020.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For LUPIN LIMITED

RAJVARDH
AN VISHNU
SATAM

Digitally signed by RAJVARDHAN
VISHNU SATAM
DN: cn=Personal,
postalCode=400062, st=Maharashtra,
c=IN, email=rajvardhan.vishnu@lupin.com,
serialNumber=dff8ba088c79663c7
8ba2759a0a475d19d72dcdb67a2f09
c42427713a, cn=RAJVARDHAN
VISHNU SATAM
Date: 2020.05.14 09:39:50 +05'30'

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl- : a/a.

Lupin's Vizag API Facility Receives EIR from U.S. FDA

Mumbai, India, May 14, 2020: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) after closure of the inspection for its Vizag (Vishakhapatnam), India facility. The inspection for the API facility was conducted by the U.S. FDA between January 13, 2020 and January 17, 2020.

Commenting on the receipt of the EIR, **Nilesh Gupta, Managing Director, Lupin** said, *"We are very happy to have received the EIR for our Vizag facility. We remain committed to enhancing compliance and quality standards at the Vizag facility and across all our manufacturing sites."*

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/

Facebook: www.facebook.com/LupinWorld/

For further information or queries please contact –

Arvind Bothra

Head – Investor Relations and Corporate Communications

Email: arvindbothra@lupin.com

Tel: +91 22 6640 8237

Manjira Sharma

General Manager – Corporate Communications

Email: manjirasharma@lupin.com

Tel: +91 22 6640 2532